Archemix’s expertise and extensive IP portfolio, associated with the discovery and development of aptamers, has resulted in its latest agreement with the Japanese company, Ribomic. The license to access certain rights from Archemix’s IP portfolio is non-exclusive, but Ribomic has the option to convert it to an exclusive license for a particular target subject to a fee.